This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Noninvasive radiomic analysis of enhanced CT predicts CTLA4 expression and prognosis in head and neck squamous cell carcinoma
Scientific Reports Open Access 05 October 2023
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Original article
Boyer, M. et al. Pembrolizumab plus ipilimumab or placebo for metastatic non–small-cell lung cancer with PD-L1 tumor proportion score ≥50%: randomized, double-blind phase III KEYNOTE-598 study. J. Clin. Oncol. https://doi.org/10.1200/JCO.20.03579 (2021)
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Sidaway, P. Ipilimumab can be safely omitted. Nat Rev Clin Oncol 18, 194 (2021). https://doi.org/10.1038/s41571-021-00483-3
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41571-021-00483-3